List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 19 studies with search of: blepharitis
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis
Condition: Blepharitis
Intervention: Drug: AzaSite®
2 Completed Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis
Condition: Blepharitis
Intervention: Drug: AzaSite®
3 Completed Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis
Condition: Blepharitis
Intervention: Drug: AzaSite®
4 Completed Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis
Condition: Blepharitis
Intervention: Drug: AzaSite®
5 Recruiting Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis
Conditions: Blepharitis;   Conjunctivitis;   Keratitis
Interventions: Drug: Moxifloxacin and Dexamethasone combined;   Drug: Moxifloxacin;   Drug: Dexamethasone
6 Recruiting Topical IL-1-Ra for Treatment of Posterior Blepharitis
Condition: Posterior Blepharitis
Interventions: Drug: 2.5% IL-1Ra;   Drug: Placebo;   Drug: 5% IL-1Ra
7 Completed Treatment of Patients With Blepharitis and Facial Rosacea
Conditions: Blepharitis;   Meibomianitis;   Dry Eye
Interventions: Drug: doxycycline;   Drug: placebo
8 Active, not recruiting The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period
Condition: Blepharitis
Interventions: Drug: Azithromycin ophthalmic solution, 1%;   Drug: Placebo
9 Recruiting The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period
Condition: Blepharitis
Interventions: Drug: Azithromycin ophthalmic solution, 1%;   Drug: Placebo
10 Terminated A Prospective Clinical Study Assessing the Effects of Tetracycline Antibiotic on Tear Film and Tear Lipid Composition Within a Population of Patients Diagnosed With Blepharitis and Dry Eye Disease
Condition: Dry Eye Syndrome
Intervention: Drug: Tetracycline: Doxycycline analog
11 Completed Evaluation and Treatment of Patients With Corneal and External Diseases
Conditions: Blepharitis;   Conjunctivitis;   Corneal Disease;   Dacryoadenitis;   Dacryocystitis;   Keratitis
Intervention:
12 Recruiting Lipids of the Human Tear Film and Their Effect on Tear Stability
Condition: Blepharitis
Interventions: Drug: doxycycline;   Drug: essential fatty acid;   Drug: azithromycin
13 Not yet recruiting Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes
Conditions: Xerophthalmia;   Blepharitis
Interventions: Drug: Systane Ultra eyedrops;   Drug: Refresh eye drops
14 Terminated A Phase II Study of AL-15469A /AL-38905 for Treatment of Marginal Corneal Infiltrates
Condition: Marginal Corneal Infiltrates
Intervention: Drug: AL-15469A / AL-38905 Ophthalmic Formulation
15 Recruiting A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome
Condition: Dry Eye Syndrome
Intervention: Drug: Essential fatty acid supplement
16 Completed Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points
Condition: Keratoconjunctivitis Sicca
Interventions: Drug: Systane Ocular Drops (OTC);   Drug: Placebo - Saline Drops
17 Completed Zylet vs TobraDex in Blepharokeratoconjunctivitis
Condition: Blepharokeratoconjunctivitis
Interventions: Drug: Loteprednol etabonate and tobramycin ophthalmic suspension;   Drug: Tobramycin and dexamethasone ophthalmic suspension
18 Completed Evaluation and Treatment of Eye Complications of Vaccinia Vaccination
Condition: Vaccinia
Intervention: Drug: NP-016 Vaccine Immune Globulin (IV-VIG)
19 Not yet recruiting Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye
Conditions: Dry Eye Syndromes;   Keratoconjunctivitis Sicca
Interventions: Drug: carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);   Drug: sodium hyaluronate 0.18% (VISMED® Multi)

Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services